Professional
Added to YB: 2025-07-22
Pitch date: 2025-07-19
PRPO [neutral]
Precipio, Inc.
+65.66%
current return
Author Info
Deep Sail Capital's strategy puts more emphasis on business models and growth potential than solely on valuations. They seek to understand in depth the industry dynamics of the companies we are invested in. The fund has three core investment focuses: quality, microcaps, and special situations. Follow on Twitter/X.
Company Info
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Market Cap
$31.3M
Pitch Price
$14.50
Price Target
38.00 (+58%)
Dividend
N/A
EV/EBITDA
-84.58
P/E
-23.65
EV/Sales
1.43
Sector
Health Care Providers and Services
Category
growth
Deep Sail Capital Portfolio Holding: Precipio, Inc.
PRPO (holding update): Specialty cancer diagnostics co w/ HemeScreen assays & IV-Cell media. Q1 pathology rev +53% YoY, margins improved (42% vs 24%). Q1 2025 MolDx approval adds $1M/yr at 100% margin. Near cashflow breakeven, $22M EV (~1x rev) vs peers at 3-11x. Target $25-38 (2-3x 2025 rev of $27M). Mgmt aligned w/ performance-based options.
Read full article (9 min)